These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32810927)

  • 1. A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P
    Grailhe P; Boutarfa-Madec A; Beauverger P; Janiak P; Parkar AA
    FEBS Open Bio; 2020 Oct; 10(10):2010-2020. PubMed ID: 32810927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A G protein-biased S1P
    Poirier B; Briand V; Kadereit D; Schäfer M; Wohlfart P; Philippo MC; Caillaud D; Gouraud L; Grailhe P; Bidouard JP; Trellu M; Muslin AJ; Janiak P; Parkar AA
    Sci Signal; 2020 Jun; 13(634):. PubMed ID: 32487716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
    Bergougnan L; Armani S; Golor G; Tardat A; Vitse O; Hurbin F; Scemama M; Poitiers F; Radzik D; Gaudin C; Hovsepian L; Muslin AJ; Kirkesseli S; Deutsch P; Parkar AA
    Br J Clin Pharmacol; 2021 Feb; 87(2):598-611. PubMed ID: 32520410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
    Bergougnan L; Andersen G; Plum-Mörschel L; Evaristi MF; Poirier B; Tardat A; Ermer M; Herbrand T; Arrubla J; Coester HV; Sansone R; Heiss C; Vitse O; Hurbin F; Boiron R; Benain X; Radzik D; Janiak P; Muslin AJ; Hovsepian L; Kirkesseli S; Deutsch P; Parkar AA
    Br J Clin Pharmacol; 2021 May; 87(5):2303-2320. PubMed ID: 33125753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.
    Spampinato SF; Merlo S; Sano Y; Kanda T; Sortino MA
    Biochem Pharmacol; 2021 Apr; 186():114465. PubMed ID: 33577891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
    Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
    Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A G-protein-biased S1P1 agonist, SAR247799, improved LVH and diastolic function in a rat model of metabolic syndrome.
    Evaristi MF; Poirier B; Chénedé X; Lefebvre AM; Roccon A; Gillot F; Beeské S; Corbier A; Pruniaux-Harnist MP; Janiak P; Parkar AA
    PLoS One; 2022; 17(1):e0257929. PubMed ID: 35030174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine 1-Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex-Induced Vascular Injury.
    Burg N; Swendeman S; Worgall S; Hla T; Salmon JE
    Arthritis Rheumatol; 2018 Nov; 70(11):1879-1889. PubMed ID: 29781582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial S1P
    Nitzsche A; Poittevin M; Benarab A; Bonnin P; Faraco G; Uchida H; Favre J; Garcia-Bonilla L; Garcia MCL; Léger PL; Thérond P; Mathivet T; Autret G; Baudrie V; Couty L; Kono M; Chevallier A; Niazi H; Tharaux PL; Chun J; Schwab SR; Eichmann A; Tavitian B; Proia RL; Charriaut-Marlangue C; Sanchez T; Kubis N; Henrion D; Iadecola C; Hla T; Camerer E
    Circ Res; 2021 Feb; 128(3):363-382. PubMed ID: 33301355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
    Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
    Cells; 2020 May; 9(5):. PubMed ID: 32455907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 16. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S1P
    Birker-Robaczewska M; Bolli M; Rey M; de Kanter R; Kohl C; Lescop C; Boucher M; Poirey S; Steiner B; Nayler O
    Mol Pharmacol; 2018 Feb; 93(2):109-118. PubMed ID: 29203519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
    Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
    Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
    Sartawi Z; Ryan KB; Waeber C
    Eur J Pharmacol; 2020 Sep; 882():173262. PubMed ID: 32534075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration.
    Yamamoto R; Aoki T; Koseki H; Fukuda M; Hirose J; Tsuji K; Takizawa K; Nakamura S; Miyata H; Hamakawa N; Kasuya H; Nozaki K; Hirayama Y; Aramori I; Narumiya S
    Br J Pharmacol; 2017 Jul; 174(13):2085-2101. PubMed ID: 28409823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.